Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00187005 · ClinicalTrials.gov registry record · Phase 3
Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
A Phase 3 study, sponsored by St. Jude Children's Research Hospital.
- Terminated
- Registry status
- Phase 3
- Development phase
- 53
- Enrollment target
NCT00187005: Clinical Trial Phase 3 study, sponsored by St. Jude Children's Research Hospital.
NCT00187005 is a Phase 3 study that was terminated before completion, run by St. Jude Children's Research Hospital. The registered enrollment target is 53 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00187005, a Phase 3 study, was terminated before completion, sponsored by St. Jude Children's Research Hospital.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 53 participants
- Enrollment target
Study Summary
The main purpose of this study is to find out if radiation to the central nervous system (CNS) can be safely omitted with early intensification of chemotherapy and chemotherapy given directly to the CNS. Another purpose is to find out if survival of children with ALL can be improved with risk-directed therapy given on this protocol.
Interventions
- DRUG Prednisone, Dexamethasone, Vincristine, Daunorubicin, PEG-L-asparaginase
- DRUG L-asparaginase, Methotrexate, Idarubicin, Etoposide, Cyclophosphamide, Cytarabine, Mercaptopurine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 1998-07 |
| Est. Completion | 2002-07 |
| Phase | Phase 3 |
Why NCT00187005 stopped before completion
NCT00187005 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Prednisone, Dexamethasone, Vincristine, Daunorubicin, PEG-L-asparaginase is the first listed.
NCT00187005 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00187005 about?
NCT00187005 is a clinical study titled "Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia". The main purpose of this study is to find out if radiation to the central nervous system (CNS) can be safely omitted with early intensification of chemotherapy and chemotherapy given directly to the CNS. Another purpose is to find out if survival of children with ALL can be improved with risk-direct...
What is the current status of trial NCT00187005?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 53 participants. The study started on 1998-07. Estimated completion is 2002-07.
What interventions are being tested in trial NCT00187005?
The interventions under investigation include: Prednisone, Dexamethasone, Vincristine, Daunorubicin, PEG-L-asparaginase (DRUG), L-asparaginase, Methotrexate, Idarubicin, Etoposide, Cyclophosphamide, Cytarabine, Mercaptopurine (DRUG).
Who is sponsoring clinical trial NCT00187005?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00187005's enrollment target sits among peer trials
53 1839th of 2000 higher than 160 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia